Skip to Main Content

Try STAT+ TODAY

generic drugs

Most Read

First Opinion John LaMattina

Even me-too drugs matter when it comes to new medicines

Politics Lev Facher

STAT Plus: A court struck down a ban on pharma ‘price gouging.’ One state wants to revive it — and others could follow

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Feds may soon charge generic drug makers for price fixing

Pharmalot Ed Silverman

Generic drug makers challenge FDA plan to withdraw their ADHD pills

First Opinion Farasat A.S. Bokhari

STAT Plus: Clinton’s proposed ban on pay-for-delay deals would do little to lower drug prices

Pharmalot Ed Silverman

Feds probe drug maker for prices of generic dermatology meds

Pharmalot Ed Silverman

Drug maker loses appeal of antitrust pay-to-delay case in Europe

Pharmalot Ed Silverman

How Mylan tried to keep Teva from selling a generic EpiPen

All Coverage

Pharmalot Ed Silverman

AstraZeneca loses court battle to prevent generic versions of Crestor

Pharmalot Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

advertisement

Pharmalot Ed Silverman

FDA narrowly defines the ability of compounders to make approved medicines

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Was the FDA commissioner paid by drug makers last year?

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Endo may sell assets as reliance on price hikes wanes

Pharmalot Ed Silverman

India makes it easier to buy its generic drug makers, but will anyone bite?

Pharmalot Ed Silverman

Former FDA official charged with securities fraud for tipping off hedge fund

Pharmalot Ed Silverman

Lawmakers look to prevent drug makers from thwarting generic competition

Pharmalot Ed Silverman

India’s new patent policy spurs debate over implications for pharma

Pharmalot Ed Silverman

FDA again delays rule to allow generic drug makers to change labels

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Walmart and McKesson team up to buy generic drugs

Pharmalot Ed Silverman

What generics? Americans spent an extra $73b for brand-name meds

The Pharmalot View Ed Silverman

Generic drug labels don’t always list known side effects. It’s time to change that

Pharmalot Ed Silverman

Glaxo, other drug makers appeal UK fines for pay-to-delay deals

Pharmalot Ed Silverman

FDA warns another Indian drug maker on serious quality control lapses

Pharmalot Ed Silverman

Two drug makers complain India is thwarting licenses for selling generics

Pharmalot Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers